These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36237358)

  • 21. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings--preliminary results.
    Makkat S; Luypaert R; Stadnik T; Bourgain C; Sourbron S; Dujardin M; De Greve J; De Mey J
    Radiology; 2008 Nov; 249(2):471-82. PubMed ID: 18780825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer.
    Qiao EQ; Ji M; Wu J; Li J; Xu X; Ma R; Zhang X; He Y; Zha Q; Song X; Zhu L; Tang JH
    Mol Clin Oncol; 2013 Jul; 1(4):703-710. PubMed ID: 24649232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of DCE-MRI Perfusion Parameters and Molecular Biology of Breast Infiltrating Ductal Carcinoma.
    Liu L; Mei N; Yin B; Peng W
    Front Oncol; 2021; 11():561735. PubMed ID: 34722229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use.
    Chand P; Garg A; Singla V; Rani N
    Niger J Surg; 2018; 24(2):100-106. PubMed ID: 30283220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI texture analysis in differentiating luminal A and luminal B breast cancer molecular subtypes - a feasibility study.
    Holli-Helenius K; Salminen A; Rinta-Kiikka I; Koskivuo I; Brück N; Boström P; Parkkola R
    BMC Med Imaging; 2017 Dec; 17(1):69. PubMed ID: 29284425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: A study from North India.
    Marwah N; Batra A; Marwah S; Gupta V; Shakya S; Sen R
    J Cancer Res Ther; 2018; 14(3):537-542. PubMed ID: 29893312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility analysis of early temporal kinetics as a surrogate marker for breast tumor type, grade, and aggressiveness.
    Heacock L; Lewin AA; Gao Y; Babb JS; Heller SL; Melsaether AN; Bagadiya N; Kim SG; Moy L
    J Magn Reson Imaging; 2018 Jun; 47(6):1692-1700. PubMed ID: 29178258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
    AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer.
    Jiang S; Hong YJ; Zhang F; Li YK
    Sci Rep; 2017 Oct; 7(1):13818. PubMed ID: 29062076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma.
    Kim EJ; Kim SH; Park GE; Kang BJ; Song BJ; Kim YJ; Lee D; Ahn H; Kim I; Son YH; Grimm R
    J Magn Reson Imaging; 2015 Dec; 42(6):1666-78. PubMed ID: 25919239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
    Senel F
    Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer.
    Baltzer PA; Vag T; Dietzel M; Beger S; Freiberg C; Gajda M; Camara O; Kaiser WA
    Eur Radiol; 2010 Jul; 20(7):1563-71. PubMed ID: 20204647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
    Incoronato M; Grimaldi AM; Cavaliere C; Inglese M; Mirabelli P; Monti S; Ferbo U; Nicolai E; Soricelli A; Catalano OA; Aiello M; Salvatore M
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1680-1693. PubMed ID: 29696443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diffusion MRI signature index is highly correlated with immunohistochemical status and molecular subtype of invasive breast carcinoma.
    Goto M; Le Bihan D; Sakai K; Yamada K
    Eur Radiol; 2022 Jul; 32(7):4879-4888. PubMed ID: 35394179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
    Prat A; Cheang MC; Martín M; Parker JS; Carrasco E; Caballero R; Tyldesley S; Gelmon K; Bernard PS; Nielsen TO; Perou CM
    J Clin Oncol; 2013 Jan; 31(2):203-9. PubMed ID: 23233704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.